|
|
|
||
|
|
||
|
||
| Title: | High-dose Melphalan Followed by Autologous Stem Cell Transplantation and Posttransplant Thalidomide Therapy for Chemotherapy-responsive Multiple Myeloma |
|---|---|
|
|
| Phase: | II |
|
|
| Purpose: | To determine effectiveness and best-tolerated dose of thalidomide in combination with high-dose chemotherapy and transplant |
|
|
| Eligibility: |
|
|
|
| Treatment: | At 100 days post stem cell transplant, patients start 200 mg per day of oral thalidomide. The dose is increased as tolerated |
|
|
| Contact: |
Wisconsin University of Wisconsin Comprehensive Cancer Center Dr Walter Longo 608-263-8629 |
|
|
| Please note: the trials indicated do not include the full inclusion or exclusion criteria. For full protocols, please contact the Principal Investigator (PI) listed. |
|
|
|
|
|
|
|